GSK-239512

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameGSK-239512
Drug Alias NameGSK-239512GSK-239512AGSK-239512-A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistamine H3 receptor antagonists
TargetsHistamine H3 receptor
Therapy Area/IndicationsSchizophreniaCognitive DysfunctionAlzheimer Disease +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[14] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsSchizophreniaCognitive DysfunctionAlzheimer Disease +[6] 

Other Information

ATC CodeN/A
Related LinksN/A